Scholarlink

Background <p><i>Legionella pneumophila</i> is a gram-negative intracellular bacteria that causes pneumonia. In severe cases, combination antimicrobial therapy using azithromycin and ciprofloxacin is recommended and critical care management may be required. Ciprofloxacin requires dose adjustment during kidney replacement therapy; however, dosing guidance during prolonged intermittent kidney replacement therapy (PIKRT) is limited. A population pharmacokinetic (PK) study based on in vitro data suggested high doses would be required to meet pharmacokinetic/pharmacodynamic (PK/PD) targets.</p> Case presentation <p>We describe the PK of intravenous ciprofloxacin in a 71-year-old male with <i>L. pneumophila</i> pneumonia requiring PIKRT. Ciprofloxacin was administered at 400&#xa0;mg IV every 12&#xa0;h, in addition to azithromycin. Ciprofloxacin PK modelling described a terminal half-life of 10.7&#xa0;h and an area under the curve over 24&#xa0;h (AUC<sub>0-24</sub>) of 130&#xa0;mg·h/L. While PK/PD targets specific to <i>L. pneumophila</i> are not established, applying the reported median minimum inhibitory concentration (MIC) for <i>Legionella</i> (0.5&#xa0;mg/L), and the gram-negative organism PK/PD target AUC<sub>1–24</sub>/MIC &gt; 125, our data supports ciprofloxacin dosing of 400&#xa0;mg IV every 12&#xa0;h during PIKRT. Contrary to the prior PK study based on in vitro data, PIKRT did not contribute additional clearance of ciprofloxacin.</p> Conclusions <p>Ciprofloxacin 400&#xa0;mg IV every 12&#xa0;h achieved adequate exposure during PIKRT, supporting this dosing regimen for treating <i>L. pneumophila</i> pneumonia. Further studies are needed to establish definitive dosing guidelines in this setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacokinetics of intravenous ciprofloxacin for Legionella pneumonia during prolonged intermittent kidney replacement therapy: a case report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • Donna Scott,
  • Sam Salman,
  • Paul Ingram,
  • Brett McWhinney,
  • Jacobus Ungerer,
  • David Morgan,
  • Jason A. Roberts,
  • Matthew Rawlins

摘要

Background

Legionella pneumophila is a gram-negative intracellular bacteria that causes pneumonia. In severe cases, combination antimicrobial therapy using azithromycin and ciprofloxacin is recommended and critical care management may be required. Ciprofloxacin requires dose adjustment during kidney replacement therapy; however, dosing guidance during prolonged intermittent kidney replacement therapy (PIKRT) is limited. A population pharmacokinetic (PK) study based on in vitro data suggested high doses would be required to meet pharmacokinetic/pharmacodynamic (PK/PD) targets.

Case presentation

We describe the PK of intravenous ciprofloxacin in a 71-year-old male with L. pneumophila pneumonia requiring PIKRT. Ciprofloxacin was administered at 400 mg IV every 12 h, in addition to azithromycin. Ciprofloxacin PK modelling described a terminal half-life of 10.7 h and an area under the curve over 24 h (AUC0-24) of 130 mg·h/L. While PK/PD targets specific to L. pneumophila are not established, applying the reported median minimum inhibitory concentration (MIC) for Legionella (0.5 mg/L), and the gram-negative organism PK/PD target AUC1–24/MIC > 125, our data supports ciprofloxacin dosing of 400 mg IV every 12 h during PIKRT. Contrary to the prior PK study based on in vitro data, PIKRT did not contribute additional clearance of ciprofloxacin.

Conclusions

Ciprofloxacin 400 mg IV every 12 h achieved adequate exposure during PIKRT, supporting this dosing regimen for treating L. pneumophila pneumonia. Further studies are needed to establish definitive dosing guidelines in this setting.